EN
FR
Disease areas
Products
Sustainable business
Careers
About us
Patient help
Accessibility
Investigator Sponsored Studies
Grants & Donations
Compounded Medicines
News & media
Contact us
Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy
2025.05.02
SCORE analysis of semaglutide 2.4 mg demonstrated risk reduction in cardiovascular events in a real-world setting
2025.03.31
Semaglutide 2.4 mg reduces burden of total cardiovascular events in people with established cardiovascular disease and overweight or obesity
2025.03.31
Growing Healthy Places: Mississauga to support children’s health and well-being across the city
2025.03.20
Health Canada approves Wegovy
®
(semaglutide injection) to reduce the risk of non-fatal myocardial infarction
2024.11.27
Léger survey shows four out of five Quebecers call for greater support for obesity from the government and public health system
2024.10.21
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
2023.08.10
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
2023.04.12
Creation of a National Training Program for Healthcare Professionals Involved in Obesity Prevention and Care
2022.04.05
Continued Support for Banting and Best’s Insulin Discovery and Research at the University of Toronto
2021.04.12
Novo Nordisk and the University of Toronto announce joint 200 DKK million investment to address diabetes and chronic disease prevention
2021.02.24
Camp Huronda receives $1.5M donation to rebuild on-site medical centre
2021.01.14
Camp Huronda infographic
2021.01.14